NasdaqGS:QURE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands.


Snowflake Analysis

Excellent balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has uniQure's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: QURE's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.7%

QURE

0.4%

US Biotechs

2.3%

US Market


1 Year Return

-36.7%

QURE

28.5%

US Biotechs

6.7%

US Market

Return vs Industry: QURE underperformed the US Biotechs industry which returned 28.5% over the past year.

Return vs Market: QURE underperformed the US Market which returned 6.7% over the past year.


Shareholder returns

QUREIndustryMarket
7 Day-1.7%0.4%2.3%
30 Day-30.2%10.3%6.0%
90 Day-19.7%23.2%18.9%
1 Year-36.7%-36.7%29.8%28.5%9.0%6.7%
3 Year580.1%580.1%31.8%27.5%36.6%27.7%
5 Year62.9%62.9%-5.1%-10.5%64.2%46.1%

Price Volatility Vs. Market

How volatile is uniQure's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is uniQure undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: QURE ($44.07) is trading below our estimate of fair value ($275.99)

Significantly Below Fair Value: QURE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: QURE is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: QURE is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate QURE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: QURE is overvalued based on its PB Ratio (5.8x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is uniQure forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?

49.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: QURE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: QURE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: QURE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: QURE's revenue (43.1% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: QURE's revenue (43.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: QURE is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has uniQure performed over the past 5 years?

-11.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: QURE is currently unprofitable.

Growing Profit Margin: QURE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: QURE is unprofitable, and losses have increased over the past 5 years at a rate of -11.5% per year.

Accelerating Growth: Unable to compare QURE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: QURE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: QURE has a negative Return on Equity (-42.16%), as it is currently unprofitable.


Next Steps

Financial Health

How is uniQure's financial position?


Financial Position Analysis

Short Term Liabilities: QURE's short term assets ($349.6M) exceed its short term liabilities ($27.1M).

Long Term Liabilities: QURE's short term assets ($349.6M) exceed its long term liabilities ($92.0M).


Debt to Equity History and Analysis

Debt Level: QURE's debt to equity ratio (12.3%) is considered satisfactory.

Reducing Debt: QURE's debt to equity ratio has reduced from 58.1% to 12.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: QURE has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if QURE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is uniQure current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate QURE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate QURE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if QURE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QURE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of QURE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Matt Kapusta (48yo)

3.58yrs

Tenure

US$4,719,955

Compensation

Mr. Matthew Craig Kapusta, also known as Matt, has been the Chief Executive Officer of uniQure N.V. since December 19, 2016 and serves as its Chief Financial Officer. Mr. Kapusta served as a Chief Financia ...


CEO Compensation Analysis

Compensation vs Market: Matt's total compensation ($USD4.72M) is about average for companies of similar size in the US market ($USD4.72M).

Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Matthew Kapusta
CEO, CFO & Executive Director3.58yrsUS$4.72m0.55% $10.7m
Sander van Deventer
Co-Founderno dataUS$1.19m0.047% $920.4k
Alexander Kuta
Executive Vice President of Operations0.92yrUS$1.35m0.012% $241.7k
Robert Gut
Chief Medical Officer & Executive Director2.08yrsUS$1.95m0.0025% $49.4k
Hugo Katus
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany5.92yrsno datano data
Christian Klemt
Chief Accounting Officer2.92yrsno data0.095% $1.9m
Maria Cantor
Senior Vice President of Investor Relations & Communication4.08yrsUS$1.22mno data
David Cerveny
Chief Legal Officer2.33yrsno datano data
Tamara Tugal
Business Development Director12.08yrsno datano data
Jonathan Garen
Chief Business Officer4yrsUS$1.32mno data

3.3yrs

Average Tenure

53.5yo

Average Age

Experienced Management: QURE's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Matthew Kapusta
CEO, CFO & Executive Director3.58yrsUS$4.72m0.55% $10.7m
Robert Gut
Chief Medical Officer & Executive Director2.08yrsUS$1.95m0.0025% $49.4k
Hugo Katus
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany5.92yrsno datano data
Michael Hayden
Member of Scientific Advisory Boardno datano datano data
Philip Astley-Sparke
Independent Chairman3.83yrsUS$282.96k0.014% $264.7k
Katherine High
Member of Scientific Advisory Boardno datano datano data
Jack Kaye
Independent Non-Executive Director4.08yrsUS$255.81k0.032% $622.7k
Jesús Prieto
Member of Scientific Advisory Boardno datano datano data
Robin Ali
Member of Scientific Advisory Boardno datano datano data
Madhavan Balachandran
Independent Non-Executive Director2.83yrsUS$247.91k0.014% $264.7k
Jeremy Springhorn
Independent Non-Executive Director2.83yrsUS$255.41k0.014% $264.7k
Paula Soteropoulos
Independent Non-Executive Director7yrsUS$230.01k0.0055% $106.8k

4.0yrs

Average Tenure

58yo

Average Age

Experienced Board: QURE's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.2%.


Top Shareholders

Company Information

uniQure N.V.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: uniQure N.V.
  • Ticker: QURE
  • Exchange: NasdaqGS
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.952b
  • Shares outstanding: 44.29m
  • Website: https://www.uniqure.com

Number of Employees


Location

  • uniQure N.V.
  • Paasheuvelweg 25a
  • Amsterdam
  • Noord-Holland
  • 1105 BP
  • Netherlands

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
QURENasdaqGS (Nasdaq Global Select)YesOrdinary SharesUSUSDFeb 2014
0EE0LSE (London Stock Exchange)YesOrdinary SharesGBUSDFeb 2014

Biography

uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/13 23:56
End of Day Share Price2020/07/13 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.